There comes a time when people lose interest in almost every good medical idea. The prototype is real. There is a real need. But once they get to that point—through regulation, clinical adoption, and commercialization—most innovations quietly go away. Clinicians, researchers, and investors have been upset about this gap for years. It looks like Scotland has made up its mind to do something about it.
The University of Glasgow is starting an MSc in MedTech Innovation in September. This program is designed to address the issue that good ideas don’t always turn into useful products. The 12-month program was created with help from NHS Greater Glasgow & Clyde, innovation hubs, and industry partners. It teaches students about all the stages of a medical technology, from finding a clinical need that isn’t being met to navigating the regulatory system, entering the market, and growing the business. That’s a lot more than what most graduate programs try to cover.
A major partner in the program, InnoScot Health, says it is the best of its kind in the country. Executive Chair of the group Graham Watson is clear about what he thinks it could do: bring Scotland’s NHS, business, and academia closer together and create what he calls “a stronger homegrown pipeline” of MedTech innovation. People who are involved with this project sound like they’re sick of seeing Scottish talent and ideas go to other places to reach their full potential.
The network behind the show gives it a grounded rather than an aspirational feel. The West of Scotland Innovation Hub, the Scottish Ambulance Service, the National Robotarium, and many other national and international businesses are partners. Tile Bio and Lumino are two Scottish small businesses that are at the cutting edge of medical technology. Students will be able to do work experience with the NHS and top MedTech companies, which is more important than it sounds. It’s one thing to know the theory behind healthcare innovation; it’s quite another to know how a hospital procurement team really thinks.
At the end of the program, there is an Innovation Day, which is a pitch show for ideas in front of NHS leaders, investors, and business leaders, with funding opportunities from the University of Glasgow. It’s the kind of moment that either makes an idea stronger or shows its flaws early on, which could be just as helpful.
Watson says that Aurum Biosciences is a case that should be looked at. Dr. David Brennan, the company’s CEO, studied clinical physics at Glasgow and then worked for NHS Greater Glasgow & Clyde before starting his own business to help people in areas with a lot of medical needs. InnoScot Health helped Aurum with its early regulatory journey. It’s not common for someone to go from college hallways to running an internationally ambitious business, but it doesn’t happen by accident either. They usually need the structured support and sectoral connections that this new program is meant to offer.
It’s still not clear how quickly this kind of effort leads to results that can be measured. It takes years to properly evaluate programs like this, and there is a big enough gap between education and real-world practice in healthcare that no single course can close it by itself. But this is something interesting to watch. Scotland has both the clinical infrastructure and the academic depth, and now it looks like the institutions are willing to connect the two. It remains to be seen if that mix can bring about the next generation of global solutions, as Watson thinks it might. It’s harder to argue with the idea that you should try than not to.
